Novartis Announces MET Inhibitor Capmatinib (INC280), the First Potential Treatment for METex14 Mutated Advanced Non-Small Cell Lung Cancer, Granted Priority FDA Review

EAST HANOVER, N.J., Feb. 11, 2020 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib ' s (INC280) New Drug Application (NDA). Capmatinib is a MET...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials